Earnings ·
Becton, Dickinson and Company reported third fiscal quarter results ending June 30, 2026, with revenue of $4.98…
BDXBecton Dickinson & Co
Becton, Dickinson and Company reported third fiscal quarter results ending June 30, 2026, with revenue of $4.98 billion, a 5.4% increase as reported and 4.4% foreign currency neutral. GAAP diluted EPS from continuing operations was $1.64, while adjusted diluted EPS reached $3.23. Year-to-date cash from continuing operations rose 33.3% to $2.1 billion, and free cash flow increased 44.6% to $1.7 billion. The company updated its full-year fiscal 2026 guidance, expecting revenue growth toward the high end of its range and raising the midpoint of adjusted diluted EPS guidance to $12.62–$12.72 from a prior range of $12.52–$12.72. Becton, Dickinson and Company is a leading global medical technology company that develops transformative technologies, services, and solutions for healthcare.